StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)

Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –

IDEXX Laboratories operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

IDEXX Laboratories's operating cash flow for the twelve months ending Jun 30, 2026 was $1.37B, up 51.4% year over year. For fiscal 2025 it was $1.18B, up 27.2% from the year before. Over ten years it grew 18.2% a year on average. The highest annual figure on record is $1.18B in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.18B+27.2%
FY2024Dec 31, 2024$929.00M+2.5%
FY2023Dec 31, 2023$906.51M+66.9%
FY2022Dec 31, 2022$542.98M-28.1%
FY2021Dec 31, 2021$755.55M+16.6%
FY2020Dec 31, 2020$648.06M+41.1%
FY2019Dec 31, 2019$459.16M+14.8%
FY2018Dec 31, 2018$400.08M+7.2%
FY2017Dec 31, 2017$373.28M+10.1%
FY2016Dec 31, 2016$338.94M+52.8%
FY2015Dec 31, 2015$221.80M-6.0%
FY2014Dec 31, 2014$235.85M-4.1%
FY2013Dec 31, 2013$246.00M+10.6%
FY2012Dec 31, 2012$222.41M+2.1%
FY2011Dec 31, 2011$217.91M+21.9%
FY2010Dec 31, 2010$178.83M+2.2%
FY2009Dec 31, 2009$174.95M+22.1%
FY2008Dec 31, 2008$143.31M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$347.16M+86.9%
Q1 FY2026Mar 31, 2026$266.25M+11.9%
Q4 FY2025Dec 31, 2025$355.76M+35.8%
Q3 FY2025Sep 30, 2025$402.34M+82.8%
Q2 FY2025Jun 30, 2025$185.74M-25.2%
Q1 FY2025Mar 31, 2025$237.96M+19.8%
Q4 FY2024Dec 31, 2024$262.03M+4.9%
Q3 FY2024Sep 30, 2024$220.08M-19.2%
Q2 FY2024Jun 30, 2024$248.31M+24.0%
Q1 FY2024Mar 31, 2024$198.59M+8.0%
Q4 FY2023Dec 31, 2023$249.85M+44.1%
Q3 FY2023Sep 30, 2023$272.43M+44.1%
Q2 FY2023Jun 30, 2023$200.31M+204.2%
Q1 FY2023Mar 31, 2023$183.91M+60.3%
Q4 FY2022Dec 31, 2022$173.43M-17.4%
Q3 FY2022Sep 30, 2022$189.00M+1.0%
Q2 FY2022Jun 30, 2022$65.85M-71.9%
Q1 FY2022Mar 31, 2022$114.71M-7.8%
Q4 FY2021Dec 31, 2021$209.96M-4.1%
Q3 FY2021Sep 30, 2021$187.21M-3.1%
Q2 FY2021Jun 30, 2021$233.96M+12.4%
Q1 FY2021Mar 31, 2021$124.42M+346.4%
Q4 FY2020Dec 31, 2020$218.93M+40.9%
Q3 FY2020Sep 30, 2020$193.12M+46.0%
Q2 FY2020Jun 30, 2020$208.14M+51.8%
Q1 FY2020Mar 31, 2020$27.87M-18.9%
Q4 FY2019Dec 31, 2019$155.41M+14.6%
Q3 FY2019Sep 30, 2019$132.27M+19.5%
Q2 FY2019Jun 30, 2019$137.10M+15.4%
Q1 FY2019Mar 31, 2019$34.38M-1.5%
Q4 FY2018Dec 31, 2018$135.65M+12.0%
Q3 FY2018Sep 30, 2018$110.71M+0.0%
Q2 FY2018Jun 30, 2018$118.83M+7.8%
Q1 FY2018Mar 31, 2018$34.90M+11.6%
Q4 FY2017Dec 31, 2017$121.13M+20.2%
Q3 FY2017Sep 30, 2017$110.68M+10.3%
Q2 FY2017Jun 30, 2017$110.19M–
Q1 FY2017Mar 31, 2017$31.27M–
Q4 FY2016Dec 31, 2016$100.76M–
Q3 FY2016Sep 30, 2016$100.32M–

More IDEXX Laboratories figures

See a number that looks wrong?